Loading…
Loading…
See exactly how YOLO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for YOLO and 80,000+ other tickers.
YOLO offers investors a unique pathway to the significant long-term growth prospects of the burgeoning cannabis industry. As the inaugural actively managed ETF in the U.S. dedicated exclusively to cannabis, it possesses distinct advantages. Its agile portfolio management allows for swift adjustments, a crucial capability in a dynamic marketplace that frequently experiences shifts in tradable equities and the introduction of new companies. The fund is overseen by a team with extensive capital markets experience and proven expertise in navigating highly regulated investment landscapes…
The cannabis sector continues to attract investors seeking long-term growth opportunities in 2026. Although volatility remains high, many marijuana companies are improving operations and cutting costs. At the same time, investors continue watching potential federal reform closely. Rescheduling discussions and banking reform could become major catalysts for the industry.
Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.
For marijuana stock investors, the way the industry as a whole progresses determines a great deal for them. For example, no one wants to invest in a struggling industry even if it's been trendy along the way. Now, cannabis has fallen to that path, but it's also what's making this industry one of the hottest sectors in the last 5 years. Legal cannabis has been a long uphill battle in every sense. Legislation and regulatory issues remain the biggest challenges.
Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade.
Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.